Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

IFITM3 found to be critical regulator of immunotherapy sensitivity in small cell lung cancer

New research presented identifies interferon-induced transmembrane protein 3 (IFITM3) as a critical regulator of immunotherapy sensitivity in small cell lung cancer (SCLC), offering a promising new avenue for overcoming resistance to PD-1/PD-L1 checkpoint blockade.

9 Sep 2025

Monitoring ctDNA can personalize the use of consolidation immunotherapy in patients with LS-SCLC

A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) demonstrates that monitoring circulating tumor DNA (ctDNA) can refine and personalize the use of consolidation immunotherapy in patients with limited-stage small cell lung cancer (LS-SCLC).

9 Sep 2025

Tarlatamab and anti-PD-L1 therapy combination demonstrates manageable safety profile in first-line ES-SCLC

Clinical data presented today demonstrates the combination of tarlatamab with anti-PD-L1 therapy as first-line maintenance has an acceptable safety profile and resulted in unprecedented overall survival in patients with extensive-stage small cell lung cancer (ES-SCLC).

8 Sep 2025

HypoRT with concurrent chemotherapy reduces treatment time and toxicity for patients with LS-SCLC

A multi-center, randomized phase III trial has found that a three-week hypofractionated radiotherapy (HypoRT) schedule with concurrent chemotherapy provides similar survival outcomes and reduced toxicity compared to the standard six-week conventional fractionated radiotherapy (ConvRT) schedule for patients with limited-stage small cell lung cancer (LS-SCLC).

8 Sep 2025

Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests

Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest that adjuvant chemo-immunotherapy may reduce the risk of recurrence in patients with completely resected stage IB–IIIA non-small cell lung cancer (NSCLC) while maintaining an acceptable safety profile.

8 Sep 2025

Ifinatamab deruxtecan may benefit patients with recurrent or progressive ES-SCLC

Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug conjugate, according to data presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.

8 Sep 2025

Osimertinib plus chemotherapy offers overall survival advantage for patients with EGFR-mutated advanced NSCLC

Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC).

8 Sep 2025

New antibody-drug conjugate iza-bren may offer promising treatment option for EGFR-mutated NSCLC patients

A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrated encouraging safety and efficacy results in previously treated patients with EGFR-mutated non-small cell lung cancer (NSCLC), according to findings presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).

8 Sep 2025

Ivonescimab plus chemotherapy provides survival benefit for difficult-to-treat NSCLC patients

Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged progression-free survival (PFS) compared to chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations whose disease progressed on third-generation EGFR tyrosine kinase inhibitors (TKIs).

8 Sep 2025

Video-assisted thoracoscopic surgery provides improved overall survival compared to open lobectomy

Patients who underwent video-assisted thoracoscopic surgery (VATS) compared to open lobectomy had a significantly improved overall survival rate, according to a meta-analysis presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).

8 Sep 2025

BioDlink fast-tracks global growth with bevacizumab launch in Colombia and Pakistan

BioDlink announced that its self-developed bevacizumab injection biosimilar has received marketing approval from Colombia’s National Institute for Surveillance of Medicines and Foods (INVIMA) and Pakistan’s Drug Regulatory Authority of Pakistan (DRAP).

From BioDlink 8 Sep 2025

WHO expands essential medicines lists with new cancer and diabetes treatments

Today, the World Health Organization (WHO) has released updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc), adding new treatments for various types of cancer and for diabetes with associated comorbidities such as obesity.

5 Sep 2025

Bacteria and viruses team up to target cancer

Researchers at Columbia Engineering have built a cancer therapy that makes bacteria and viruses work as a team.

18 Aug 2025

Nanobody breakthrough offers precise targeting of lung cancer cells

A research team led by Dr. Juyeon Jung at the Bio-Nano Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), has developed a nanobody-based technology that can precisely identify and attack only lung cancer cells, opening new possibilities for cancer therapy.

17 Aug 2025

Adding MET inhibitor enhances immune response against small cell lung tumors

Adding a MET gene inhibitor enhances the effect of combined chemotherapy and immunotherapy in small cell lung cancer (SCLC), according to a multicenter study led by the Hospital del Mar Research Institute, in collaboration with researchers from the CIBERONC cancer research network.

12 Aug 2025

Gfi1 regulates exhausted CD8+ T cells to improve cancer immunotherapy

Killer immune cells destroy cancer cells and cells infected by virus. These CD8+ T cells are activated after detection of viral infection or growth of "non-self" tumor cells.

5 Aug 2025

Eating more ultra-processed food raises your risk of lung cancer

The association between ultra-processed food consumption and lung cancer risk underscores the importance of nutrition in cancer prevention strategies.

4 Aug 2025

Moffitt launches research-driven initiative to improve outcomes for Black lung cancer patients

Lung cancer, particularly non-small cell lung cancer, affects millions of people worldwide, but the survival rates and access to care are notably lower among Black patients.

1 Aug 2025

Artificial sweetener may undermine effectiveness of cancer treatment

Sucralose is a popular sugar substitute for people who are cutting calories or managing blood sugar levels, but new research by the University of Pittsburgh and UPMC Hillman Cancer Center suggests that the artificial sweetener may not be the best choice for patients undergoing cancer immunotherapy.

31 Jul 2025

Novel insights from lymphoid structures: Lessons from colorectal cancer research

Discover how lymphoid structures and germinal centers provide powerful prognostic insights into colorectal cancer.

From TissueGnostics 31 Jul 2025

Small Cell Lung Cancer News and Research

IFITM3 found to be critical regulator of immunotherapy sensitivity in small cell lung cancer

Monitoring ctDNA can personalize the use of consolidation immunotherapy in patients with LS-SCLC

Tarlatamab and anti-PD-L1 therapy combination demonstrates manageable safety profile in first-line ES-SCLC

HypoRT with concurrent chemotherapy reduces treatment time and toxicity for patients with LS-SCLC

Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests

Ifinatamab deruxtecan may benefit patients with recurrent or progressive ES-SCLC

Osimertinib plus chemotherapy offers overall survival advantage for patients with EGFR-mutated advanced NSCLC

New antibody-drug conjugate iza-bren may offer promising treatment option for EGFR-mutated NSCLC patients

Ivonescimab plus chemotherapy provides survival benefit for difficult-to-treat NSCLC patients

Video-assisted thoracoscopic surgery provides improved overall survival compared to open lobectomy

BioDlink fast-tracks global growth with bevacizumab launch in Colombia and Pakistan

WHO expands essential medicines lists with new cancer and diabetes treatments

Bacteria and viruses team up to target cancer

Nanobody breakthrough offers precise targeting of lung cancer cells

Adding MET inhibitor enhances immune response against small cell lung tumors

Gfi1 regulates exhausted CD8+ T cells to improve cancer immunotherapy

Eating more ultra-processed food raises your risk of lung cancer

Moffitt launches research-driven initiative to improve outcomes for Black lung cancer patients

Artificial sweetener may undermine effectiveness of cancer treatment

Novel insights from lymphoid structures: Lessons from colorectal cancer research

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News